Longitudinal changes in cardiorenal risk scores after SGLT2 inhibitor initiation in patients with CKD with and without type 2 diabetes
Journal of Nephrology · 2026
DOI: 10.1093/joneph/aajag105 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nephrology, 2026. Verfasst von Irene Capelli und 10 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Renal Insufficiency, Chronic, Cardiovascular Diseases. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Sodium–glucose cotransporter-2 inhibitors (SGLT2i) have become the standard of care in managing chronic kidney disease (CKD) and heart failure (HF), both in patients with and without type 2 diabetes mellitus (T2DM). Nonetheless, identifying those at persistent high cardiovascular (CV) and renal risk remains critical.
Methods
We conducted a retrospective, 1:1 propensity-matched cohort study involving 132 CKD patients (66 with T2D and 66 without). Participants were followed for 12 months after SGLT2i initiation. Cardiovascular and renal risk were assessed using three validated tools—PREVENT, SCORE2 with CKD Add-on (SCORE2-CKD), and Kidney Failure Risk Equation (KFRE)—calculated at baseline and at 12-month follow-up. Changes in risk scores were analyzed, and logistic regression was used to identify predictors of improvement.
Results
After 12 months, PREVENT scores declined significantly in the diabetic subgroup (Δ −2.95, P = .001), whereas non-diabetic patients showed no significant change (Δ −0.80, P = .396). SCORE2-CKD also decreased in diabetics (Δ −3.85, 95% CI −4.35 to −3.35, P = .023) but unexpectedly increased in non-diabetic patients (Δ + 3.25, P = .044). Importantly, individuals at higher baseline risk exhibited the most pronounced declines in both PREVENT and SCORE2-CKD. KFRE-derived renal risk decreased significantly in both groups. Across the entire cohort, variation in estimated glomerular filtration rate (eGFR) and proteinuria were independent predictors of CV risk-score improvement.
Conclusions
In this real-world CKD cohort, SGLT2 inhibitor initiation was associated with favorable changes in renal risk scores and with changes in cardiovascular risk estimates, particularly among patients with diabetes and at higher baseline risk. These findings should be interpreted as exploratory changes in predicted risk rather than as evidence of reduction in observed cardiovascular events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna, Bologna, Italy.
- Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Nephrology, Dialysis and Renal Transplant Unit, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende - Hospital 'SS. Annunziata', Cosenza, Italy.
ORCID-Profile: Daniele Vetrano, Michele Provenzano, Sabrina Berti, Uberto Pagotto, Gaetano La Manna
Zitieren
APA
Capelli, I., Vetrano, D., Ribichini, D., Provenzano, M., Albertini, S., Berti, S., Sanfilippo, I., Vicennati, V., Pagotto, U., La Manna, G., & Cianciolo, G. (2026). Longitudinal changes in cardiorenal risk scores after SGLT2 inhibitor initiation in patients with CKD with and without type 2 diabetes. Journal of Nephrology. https://doi.org/10.1093/joneph/aajag105
Vancouver
Capelli I, Vetrano D, Ribichini D, Provenzano M, Albertini S, Berti S, et al. Longitudinal changes in cardiorenal risk scores after SGLT2 inhibitor initiation in patients with CKD with and without type 2 diabetes. Journal of Nephrology. 2026. doi:10.1093/joneph/aajag105
BibTeX
@article{Capelli2026,
author = {Capelli, Irene and Vetrano, Daniele and Ribichini, Danilo and Provenzano, Michele and Albertini, Sasha and Berti, Sabrina and Sanfilippo, Ilirjana and Vicennati, Valentina and Pagotto, Uberto and La Manna, Gaetano and Cianciolo, Giuseppe},
title = {Longitudinal changes in cardiorenal risk scores after SGLT2 inhibitor initiation in patients with CKD with and without type 2 diabetes},
journal = {Journal of Nephrology},
year = {2026},
doi = {10.1093/joneph/aajag105}
}
EUVIMED